NPPA Issues Demand Notice to GlaxoSmithKline Pharmaceuticals Over Alleged Price Violations
GlaxoSmithKline Pharmaceuticals Ltd has received a Demand Notice from the National Pharmaceutical Pricing Authority (NPPA) concerning alleged overcharging in the sale of scheduled formulations. The company was issued the notice on June 24, 2026.The NPPA's action relates to the allegation that the company charged prices higher than those fixed or notified by the Government or NPPA during the relevant period for its scheduled formulations.
A formal Demand Notice dated June 24, 2026, was issued by the National Pharmaceutical Pricing Authority. The total demand set against GlaxoSmithKline Pharmaceuticals Ltd is Rs 3,54,12,025/-. This amount comprises alleged overcharging amounting to Rs 1,22,91,163 and interest totaling Rs 2,31,20,862.
The key details of the action initiated by the authority are summarized below:
| Authority | Nature of Action | Date of Receipt | Violation Details |
|---|---|---|---|
| National Pharmaceutical Pricing Authority | Demand Notice | June 24, 2026 | Overcharged in the sale of scheduled formulations by charging price higher than the price fixed or notified by the Government/NPPA. |
Despite the demand notice, GlaxoSmithKline Pharmaceuticals Ltd stated that there will be no impact on its financial operations. The company plans to appeal against the demand order.
GLAXO Stock Price Movement
As of 11:48 AM, shares of GlaxoSmithKline Pharmaceuticals Limited are edging higher in live trading, currently at ₹2382.3 after gaining ₹15.70, or 0.66%. The stock has seen robust activity so far today, with a volume of 26,565 shares traded.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.